Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06170970 · ClinicalTrials.gov registry record · Phase 2
Solriamfetol for the Treatment of Multiple Sclerosis Fatigue
A Phase 2 study of Multiple Sclerosis and Multiple Sclerosis Fatigue, sponsored by Johns Hopkins University.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 46
- Enrollment target
- 1
- Study location
NCT06170970: Recruiting Phase 2 study of Multiple Sclerosis and Multiple Sclerosis Fatigue, sponsored by Johns Hopkins University.
NCT06170970 is a Phase 2 study of Multiple Sclerosis and Multiple Sclerosis Fatigue that is actively recruiting participants, run by Johns Hopkins University. The registered enrollment target is 46 participants, below the 585-participant average among 315 other Multiple Sclerosis trials with a reported enrollment target (92% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06170970, a Phase 2 study of Multiple Sclerosis and Multiple Sclerosis Fatigue, is actively recruiting participants, sponsored by Johns Hopkins University.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 46 participants
- Enrollment target
- 1
- Study location
Study Summary
Fatigue is a prevalent and disabling symptom in Multiple Sclerosis (MS), affecting up to 90% of patients. Current treatments, including off-label prescriptions of wake-promoting agents, have shown limited effectiveness. Previous research indicates that these agents may be beneficial specifically for MS patients with concomitant excessive daytime sleepiness. This study uses a randomized, double-blind, placebo-controlled crossover design. Participants will undergo a 10-day lead-in with he medication/placebo, followed by two four-week treatment periods separated by a one-week washout. Outcomes will be measured primarily using the Modified Fatigue Impact Scale (MFIS), with additional exploratory measures collected via a smartphone app that assesses fatigue through keystroke dynamics. This novel approach to fatigue measurement aims to capture real-time variations and provide more granular data than traditional self-report questionnaires.
Primary Outcome
MFIS score measured during the last three days of each 4-week medication period. The total score of the MFIS ranges from 0 to 84. Higher scores denote more severe fatigue.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Solriamfetol
Study Locations (1)
Maryland
- Johns Hopkins University - Baltimore
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 46 participants |
| Start Date | 2024-06-01 |
| Est. Completion | 2027-03-01 |
| Phase | Phase 2 |
What NCT06170970 shows while recruiting
NCT06170970 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 46 participants, a relatively small participant target, below the 585-participant average among 315 other Multiple Sclerosis trials with a reported enrollment target (92% lower).
The record links to 2 conditions, with Multiple Sclerosis appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06170970 reports a single indexed study location in Maryland.
Frequently Asked Questions
What is clinical trial NCT06170970 about?
NCT06170970 is a clinical study titled "Solriamfetol for the Treatment of Multiple Sclerosis Fatigue". Fatigue is a prevalent and disabling symptom in Multiple Sclerosis (MS), affecting up to 90% of patients. Current treatments, including off-label prescriptions of wake-promoting agents, have shown limited effectiveness. Previous research indicates that these agents may be beneficial specifically for...
What is the current status of trial NCT06170970?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 46 participants. The study started on 2024-06-01. Estimated completion is 2027-03-01.
What conditions does trial NCT06170970 study?
This clinical trial studies the following conditions: Multiple Sclerosis, Multiple Sclerosis Fatigue.
What interventions are being tested in trial NCT06170970?
The interventions under investigation include: Placebo (DRUG), Solriamfetol (DRUG).
Who is sponsoring clinical trial NCT06170970?
This trial is sponsored by Johns Hopkins University, which has 1,448 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06170970 being conducted?
This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Multiple Sclerosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06170970's enrollment target sits among peer trials
46 190th of 315 higher than 126 of 315 other Multiple Sclerosis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Multiple Sclerosis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Mechanisms of Cannabidiol in Persons With MS: the Role of Sleep and Pain Phenotype
RECRUITING · Phase 2
-
Metformin as an add-on or Monotherapy in Treatment of Aging People With Multiple Sclerosis (MS)
RECRUITING · Phase 2
-
A Study to Assess Bioequivalence of Two Subcutaneous (SC) Formulations of Ocrelizumab in Participants With Multiple Sclerosis (MS)
RECRUITING · Phase 2
-
A Study to Investigate Multiple Sclerosis Relapse Prevention With mRNA-1195 Compared With Placebo in Participants Aged 18 to ≤55 Years
RECRUITING · Phase 2
-
Efficacy of Cognitive Behavioral Therapy for Insomnia to Treat Insomnia Symptoms in Individuals With Multiple Sclerosis
RECRUITING · Phase 2
-
A Study of LY3541860 in Adult Participants With Relapsing Multiple Sclerosis
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01890590 · 46 participants · NA
A Phase II Study of Cyberknife Radiosurgery for Renal Cell Carcinoma
- NCT03191149 · 46 participants · Phase 2
Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 Change
- NCT03510208 · 46 participants · Phase 1
Panitumumab-IRDye800 in Diagnosing Participants With Malignant Glioma Undergoing Surgery
- NCT04048278 · 46 participants · Early Phase 1
Lidocaine Infusion in Pancreatic Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI